University of Calgary

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Calgary sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 3 currently recruiting 6 completed later-stage tilt top decile by trial count

University of Calgary: 11 sponsored US clinical trials, 3 recruiting.

University of Calgary sponsors 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sudden Death, with 1 trials.

Top-decile sponsor footprint

University of Calgary ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING

PROMIS and Mobility Evaluation in Sarcoma Patients

NCT07227961
RECRUITING

PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

NCT05756244
RECRUITING NA

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
COMPLETED

Asymptomatic SARS-CoV-2 Detection in Children

NCT04853316
COMPLETED Phase 3

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

NCT03582176
TERMINATED NA

Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury

NCT02232165
COMPLETED Phase 3

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

NCT00673842
COMPLETED Phase 4

Clinical Trial for the Prevention of Vasovagal Syncope

NCT00118482
TERMINATED Phase 2

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

NCT00109577
COMPLETED Phase 2

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

NCT00109382
COMPLETED Phase 4

Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

NCT00115726

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 2
Phase 4 2

Therapeutic Areas

Sudden Death 1
Elbow Fracture 1
Elbow Injury 1
Giant Cell Tumor of Bone 1
SARS-CoV-2 1
Elbow Dislocation 1
Hemolytic-Uremic Syndrome 1
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection 1
Sarcoma 1
Myocardial Infarction 1

Where University of Calgary enrollment is open (later-stage tilt)

3 recruiting of 11 indexed (27% open); 6 completed (55%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Sudden Death (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Calgary: open-pipeline peers nationwide

Peers matched on 11 registered trials and 27% open enrollment, not the therapeutic-area sidebar.

University of Calgary sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30% Total trials Recruiting share University of CalgaryAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeConnecticut Children's Medical CenterCriteriumMinneapolis Heart Institute FoundationNerviano Medical Sciences
University of Calgary sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Calgary sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 27% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Calgary page

11 registered trials is a research-attention snapshot, not an endorsement of University of Calgary or any single study.

  • 3 of University of Calgary's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Sudden Death is the condition University of Calgary studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sudden Death trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Calgary pipeline card: 11 registered trials from official public datasets.Report a data error.